10x Genomics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Shehnaaz Suliman, a Director of 10x Genomics, Inc., sold 5,723 shares of common stock on September 22, 2026.
NASDAQ
Form 4: 10x Genomics CFO Sells Shares
Adam Taich, Chief Financial Officer of 10x Genomics, Inc., sold 46,388 shares of common stock on September 9, 2026.
NASDAQ
John R Stuelpnagel, a Director of 10x Genomics, Inc., sold 20,000 shares of common stock on September 3, 2026.
NASDAQ
Form 4: 10x Genomics CEO Sells Shares
Serge Saxonov, Chief Executive Officer and a Director of 10x Genomics, Inc., sold 10,486 shares of common stock on August 26, 2026.
NASDAQ
Form 4: 10x Genomics CEO Sells Shares
Serge Saxonov, Chief Executive Officer and a Director of 10x Genomics, Inc., sold 18,545 shares of common stock on August 24, 2026 for $63.02 per share.
NASDAQ
Form 4: 10x Genomics CFO Sells Shares
Adam Taich, Chief Financial Officer of 10x Genomics, Inc., sold 17,166 shares of common stock on August 24, 2026 for $63.02 per share.
NASDAQ
Shehnaaz Suliman, a Director of 10x Genomics, Inc., sold 2,207 shares of common stock on August 24, 2026.
NASDAQ
Serge Saxonov, Chief Executive Officer and a Director of 10x Genomics, Inc., reported a transaction in 4,000 shares of common stock on August 20, 2026.
NASDAQ
Sarah A. Teichmann, a Director of 10x Genomics, Inc., sold 7,551 shares of common stock on August 13, 2026.
NASDAQ
John R Stuelpnagel, a Director of 10x Genomics, Inc., sold 20,000 shares of common stock on August 11, 2026.
NASDAQ
Serge Saxonov, CEO of 10x Genomics, has reported the sale of Class A Common Stock valued at over $25 million through a pre-arranged trading plan.
NASDAQ
10x Genomics Director Shehnaaz Suliman reported the sale of Class A Common Stock under a pre-arranged trading plan.
NASDAQ
Director Sarah Teichmann was granted 8,829 restricted stock units in 10x Genomics, Inc. as part of standard equity compensation.
NASDAQ
Director Shehnaaz Suliman was granted 8,829 restricted stock units as part of her compensation package with 10x Genomics.
NASDAQ
Director John R. Stuelpnagel was granted 8,829 restricted stock units as part of his compensation package with 10x Genomics.
NASDAQ
Director Kimberly J. Popovits was granted 8,829 restricted stock units as part of her compensation package with 10x Genomics.
NASDAQ
Director Alan Mateo was granted 8,829 restricted stock units by 10x Genomics, Inc. as part of his compensation.
NASDAQ
Director Sridhar Kosaraju was granted 8,829 restricted stock units by 10x Genomics, Inc. as part of his ongoing service.
NASDAQ
CEO Serge Saxonov sold 28,893 shares of 10x Genomics stock to cover tax obligations and via a pre-arranged trading plan.
NASDAQ
President and Chief Scientific Officer Benjamin J. Hindson sold 11,595 shares of 10x Genomics to cover tax withholding requirements.
NASDAQ
10x Genomics CFO Adam Taich sold 15,098 shares of Class A Common Stock to satisfy tax withholding obligations related to RSU vesting.
NASDAQ
CEO Serge Saxonov sold 5,000 shares of 10x Genomics Class A Common Stock via a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
10x Genomics CEO Serge Saxonov sold 15,000 shares of Class A Common Stock for approximately $289,000 through a pre-arranged 10b5-1 trading plan.
NASDAQ
10x Genomics CEO Serge Saxonov reported sales of Class A Common Stock totaling 16,152 shares and a gift of 2,750 shares under a pre-arranged 10b5-1 trading plan.
NASDAQ
10x Genomics CEO Serge Saxonov was granted 157,895 restricted stock units, aligning his interests with long-term shareholder value.
NASDAQ
10x Genomics, Inc. awarded 88,816 restricted stock units to Benjamin J. Hindson, President and Chief Scientific Officer, as part of his compensation.
NASDAQ
10x Genomics' Chief Financial Officer, Adam Taich, was granted 106,579 Restricted Stock Units, signaling long-term executive alignment.
NASDAQ
10x Genomics Director Sarah A. Teichmann sold 7,579 shares of Class A Common Stock at $19.41 per share under a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
10x Genomics CEO Serge Saxonov sold 9,632 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.
NASDAQ
10x Genomics Chief Financial Officer Adam Taich sold 8,968 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.